Analyzing Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) & Vasamed (OTCMKTS:VSMD)

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Vasamed (OTCMKTS:VSMD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Earnings and Valuation

This table compares Fresenius Medical Care AG & Co. KGaA and Vasamed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$20.63 billion	N/A	$582.08 million	$1.37	16.68
Vasamed	N/A	N/A	N/A	N/A	N/A

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Vasamed.

Institutional and Insider Ownership

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 8.0% of Vasamed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Vasamed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	3.72%	7.42%	3.43%
Vasamed	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Fresenius Medical Care AG & Co. KGaA and Vasamed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	3	3	0	0	1.50
Vasamed	0	0	0	0	0.00

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $28.00, suggesting a potential upside of 22.51%. Given Fresenius Medical Care AG & Co. KGaA’s stronger consensus rating and higher probable upside, equities analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Vasamed.

Summary

Fresenius Medical Care AG & Co. KGaA beats Vasamed on 7 of the 8 factors compared between the two stocks.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

About Vasamed

Vasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota.